Tier 2 — strong

Coenzyme Q10 supplementation in rheumatic diseases: A systematic review

Jozélio Freire de Carvalho, Thelma Skare
Clinical Nutrition ESPEN 2024 59:63-69

Bibliography

PubMed
PMID 38220408
Funding
Not reported in the accessible PubMed abstract.
Competing interests
Not reported in the accessible PubMed abstract.

Study snapshot

DesignSystematic review
ModelHuman rheumatic-disease studies
Sample20 articles; 483 patients
InterventionCoQ10 supplementation across fibromyalgia, rheumatoid arthritis and antiphospholipid syndrome studies
DurationVaried across included studies
EndpointsFibromyalgia pain and fatigue; Sleep and mood; Fibromyalgia Impact Questionnaire; Rheumatoid arthritis disease activity; Inflammatory and oxidative-stress biomarkers; Endothelial/prothrombotic markers

What the study showed, in plain terms

This systematic review identified 20 articles involving 483 patients. Fifteen studies involved fibromyalgia, where most reported improvements in pain, fatigue, sleep and Fibromyalgia Impact Questionnaire scores. The authors still called for larger confirmatory studies.

Key findings

Fibromyalgia had the largest evidence base, with smaller rheumatoid-arthritis and antiphospholipid-syndrome datasets. Signals were favorable, but the evidence should be interpreted as complementary-treatment evidence rather than proof of broad rheumatic-disease efficacy.

What this study can and cannot tell us

Small studies, heterogeneous diagnoses, doses and outcomes, and limited large confirmatory trials reduce certainty.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified